List of Excipients in Branded Drug NAPROXEN SODIUM 220MG

Generic Drugs Containing NAPROXEN SODIUM 220MG

Company	Ingredient	NDC	Excipient
Athlete's Needs Inc	naproxen sodium 220mg	53185-362	CELLULOSE, MICROCRYSTALLINE
Athlete's Needs Inc	naproxen sodium 220mg	53185-362	CROSCARMELLOSE SODIUM
Athlete's Needs Inc	naproxen sodium 220mg	53185-362	FD&C BLUE NO. 2
Athlete's Needs Inc	naproxen sodium 220mg	53185-362	HYPROMELLOSES

What are the Most Frequently-Used Excipients in NAPROXEN SODIUM 220MG?

# Of NDCs	Excipient
7	CELLULOSE, MICROCRYSTALLINE
5	CROSCARMELLOSE SODIUM
5	FD&C BLUE NO. 2
1	FD&C BLUE NO. 2 ALUMINUM LAKE

Naproxen Sodium 220 mg Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Naproxen sodium 220 mg is a mature over-the-counter NSAID with low active-ingredient cost, broad generic availability, and limited meaningful patent protection. Commercial value is concentrated in formulation performance, packaging, tolerability, brand positioning, private-label supply, and differentiated delivery formats. The standard tablet contains naproxen sodium equivalent to 200 mg naproxen and is generally labeled for adults and children 12 years and older under the FDA’s OTC internal analgesic monograph framework.[1]

What is the commercial status of naproxen sodium 220 mg?

Naproxen sodium 220 mg is an established OTC analgesic and antipyretic strength used for temporary relief of minor aches and pains, including headache, muscular pain, backache, toothache, menstrual cramps, and arthritis-related pain. The standard consumer dose is one tablet every 8 to 12 hours, with a maximum of three tablets in 24 hours unless directed by a healthcare professional.[1]

Attribute	Naproxen sodium 220 mg
Active ingredient	Naproxen sodium
Naproxen equivalent	200 mg naproxen per tablet
Drug class	Nonsteroidal anti-inflammatory drug
Primary OTC uses	Pain, fever, minor arthritis pain
Typical adult dosing	220 mg every 8 to 12 hours
Maximum OTC daily dose	660 mg naproxen sodium
Typical dosage form	Immediate-release tablet or caplet
Primary regulatory route	OTC monograph pathway
FDA monograph	21 C.F.R. § 343
Prescription-to-OTC history	Naproxen sodium was switched to OTC use in the 1990s
Primary commercial references	Aleve and store-brand equivalents
Biosimilar exposure	None
Generic substitution risk	High

Naproxen sodium has a longer duration of analgesic action than many commonly used OTC NSAIDs, which supports the product’s 8-to-12-hour dosing message. Ibuprofen remains the main direct competitive product because of its strong consumer recognition, extensive private-label supply, and wider range of pediatric and adult products.

What excipients are used in naproxen sodium 220 mg tablets?

Commercial excipient systems generally support tablet manufacturability, rapid disintegration, coating performance, physical stability, and consumer acceptability. Exact compositions differ by manufacturer and product format.

Typical excipient categories include:

Excipient function	Common candidates	Commercial purpose
Diluent or filler	Microcrystalline cellulose, lactose, dibasic calcium phosphate, starch	Provides tablet mass and improves compression
Binder	Povidone, pregelatinized starch, hydroxypropyl cellulose	Improves granule and tablet strength
Disintegrant	Croscarmellose sodium, crospovidone, sodium starch glycolate	Promotes tablet breakup and dissolution
Lubricant	Magnesium stearate, stearic acid	Reduces ejection force and tooling adhesion
Glidant	Colloidal silicon dioxide	Improves powder flow
Surfactant or wetting aid	Sodium lauryl sulfate or equivalent	Can improve wetting of hydrophobic drug particles
Film former	Hypromellose, polyvinyl alcohol	Provides coating integrity
Plasticizer	Polyethylene glycol, propylene glycol	Reduces coating brittleness
Opacifier	Titanium dioxide, where permitted	Improves appearance and light protection
Colorant	Iron oxides, approved lakes, dyes	Supports product identification
Printing system	Pharmaceutical ink components	Enables imprinting and brand differentiation

Naproxen sodium is more water soluble than naproxen, but dissolution remains sensitive to particle size, compression force, lubricant level, coating thickness, and disintegrant selection. A formulation can therefore differentiate through disintegration and dissolution without changing the active ingredient.

Which excipients are most important for performance?

The highest-value excipient decisions usually involve the disintegrant, lubricant, binder, and coating system.

Croscarmellose sodium and crospovidone are strong candidates for an immediate-release product because they support rapid tablet breakup at relatively low concentrations. Excessive compression can offset their benefit. Magnesium stearate can reduce wetting and slow dissolution when used at high levels or blended for too long.

Microcrystalline cellulose provides robust direct-compression performance and helps support smaller tablets. Pregelatinized starch can provide both binding and disintegration, which may reduce the number of excipient types. Lactose may lower cost but introduces a labeling and tolerability consideration for consumers who avoid lactose-derived ingredients.

A low-moisture formulation is generally attractive because it can improve stability and reduce the risk of tablet softening, sticking, or dissolution drift during storage. The final choice must be confirmed through development testing, including dissolution, hardness, friability, disintegration, assay, impurities, and accelerated stability.

What formulation opportunities exist for naproxen sodium 220 mg?

The most commercially credible opportunities are products that improve consumer convenience while preserving the monograph-based 220 mg strength and immediate-release profile.

Immediate-release caplet with optimized dissolution

A standard film-coated caplet is the lowest-risk development route. Opportunity exists in:

• Smaller tablet dimensions
• Faster disintegration
• Improved swallowability
• Reduced coating weight
• Gluten-free or lactose-free positioning
• Clear excipient disclosure
• Stronger resistance to chipping and abrasion

This format is suitable for private-label retail, club stores, pharmacies, and e-commerce.

Softgel or liquid-filled capsule

A liquid-filled capsule can improve swallowability and provide a differentiated appearance. Potential benefits include rapid dispersion and premium positioning. The main technical barriers are:

• Compatibility between naproxen sodium and the liquid vehicle
• Solubility limits
• Shell compatibility
• Moisture transfer
• Long-term leakage and brittleness
• Scale-up of liquid fill uniformity

A softgel product may command a higher retail price than a basic caplet, but the cost of goods and packaging is higher. The product must demonstrate appropriate dissolution and stability against the reference or applicable regulatory standard.

Chewable naproxen sodium 220 mg

A chewable product could target consumers who have difficulty swallowing tablets. The principal excipient challenges are taste masking, mouthfeel, tablet friability, and dose uniformity.

Suitable development tools may include:

• Sweeteners such as sucralose or acesulfame potassium
• Polyols such as mannitol or sorbitol
• Flavors
• Adsorbent or polymeric taste-masking systems
• Direct-compression excipients with low grittiness

Naproxen’s bitterness and potential mouth irritation make taste masking a central development issue. A chewable product also creates greater exposure to excipient load and flavor acceptance risk than a conventional coated caplet.

Orally disintegrating tablet

An orally disintegrating tablet could provide a convenience benefit without requiring water. The formulation must control:

• Mechanical strength
• Friability
• Rapid disintegration
• Moisture sensitivity
• Taste masking
• Packaging protection

Unit-dose aluminum blister packaging is more suitable than standard high-density polyethylene bottles where moisture sensitivity is material. The commercial opportunity is real but narrower than for standard caplets because the product must justify a higher price and overcome the taste-masking challenge.

Enteric-coated or gastro-resistant product

An enteric-coated naproxen sodium product could be positioned around delayed release or gastric exposure reduction. It carries higher technical and regulatory risk. Enteric coating does not eliminate systemic NSAID risks and may delay analgesic onset. It also creates more demanding dissolution specifications and greater manufacturing complexity.

The product should not be marketed as reducing ulcer, bleeding, renal, cardiovascular, or other NSAID risks unless supported by specific clinical evidence and permitted labeling.

How should excipient strategy address naproxen sodium safety?

Excipients cannot remove the core safety risks associated with systemic naproxen. The principal risks include gastrointestinal bleeding, ulceration, cardiovascular thrombotic events, renal effects, hypersensitivity reactions, and fetal harm during later pregnancy. FDA labeling also warns against combining naproxen sodium with other NSAIDs unless directed by a healthcare professional.[1]

Formulation development should focus on reliable dose delivery and appropriate label compliance rather than unsupported safety claims.

Important controls include:

1. Uniformity of dosage units across the commercial shelf life.
2. Protection from moisture and excessive heat.
3. Rapid and reproducible disintegration for immediate-release products.
4. Control of related substances and degradation products.
5. Accurate tablet identification and imprinting.
6. Packaging that reduces accidental ingestion and supports tamper evidence.
7. Consumer-readable warnings covering NSAID duplication, cardiovascular risk, gastrointestinal bleeding, pregnancy, and age restrictions.

A product intended for older adults may benefit from a smaller caplet and easy-open packaging, but easy-open features must remain compatible with child-resistant packaging requirements where applicable.

What FDA regulatory pathway applies to naproxen sodium 220 mg?

Naproxen sodium 220 mg is regulated as an OTC internal analgesic. The applicable FDA monograph framework is 21 C.F.R. § 343, which covers active ingredients, indications, warnings, directions, and related conditions for OTC internal analgesic, antipyretic, and antirheumatic products.[2]

A manufacturer using a monograph-compliant formulation and labeling can generally pursue the OTC monograph route rather than a full new drug application. A product with a novel dosage form, nonstandard delivery mechanism, new indication, or material deviation from monograph conditions may require a different regulatory strategy.

FDA exclusivity and Orange Book position

Naproxen sodium 220 mg has no meaningful remaining new-drug exclusivity period associated with the mature OTC product category. The commercial product is exposed to extensive generic and private-label competition.

The Orange Book is primarily relevant to approved prescription products and certain approved OTC products. For a new monograph-compliant OTC launch, the key regulatory controls are the OTC monograph, Drug Facts labeling, establishment registration, product listing, manufacturing compliance, and applicable quality requirements. Brand-specific Orange Book protection is not the primary commercial barrier for a standard OTC naproxen sodium product.[2,3]

What patents protect naproxen sodium 220 mg products?

The original compound and conventional naproxen sodium tablet concepts are long past their likely basic patent terms. Commercial risk is therefore unlikely to arise from a blocking composition-of-matter patent covering naproxen sodium itself.

Potential surviving or later-filed rights could concern:

• Specialized particle-size distributions
• Salt or polymorph control
• Taste-masking systems
• Liquid-filled capsules
• Controlled-release delivery
• Combination products
• Packaging systems
• Manufacturing processes
• Specific therapeutic uses

These rights would need to be assessed claim by claim. A patent covering a particular formulation does not automatically block a conventional immediate-release tablet using different excipients.

Are Paragraph IV challenges relevant?

Paragraph IV litigation is generally not the primary entry mechanism for a standard OTC monograph naproxen sodium 220 mg product. A company launching under the monograph route would more commonly address regulatory compliance and potential patent issues through a product-specific freedom-to-operate review.

Paragraph IV risk may become relevant if a company seeks approval for an NDA-based formulation, a patented delivery system, or a prescription product with listed Orange Book patents. For the conventional OTC product, the principal commercial threat is price competition rather than patent litigation.

Are settlement agreements or active litigation material?

Naproxen sodium 220 mg is a mature market with no widely recognized current litigation barrier comparable to active disputes around newer branded medicines. Any transaction or launch decision should still screen federal court dockets, the FDA Orange Book, USPTO records, and product-specific labeling because litigation status can change by dosage form or manufacturer.

How strong is the naproxen sodium 220 mg patent estate?

The patent estate is weak for the conventional product and potentially stronger for differentiated delivery systems.

Product concept	Patent risk	Development barrier	Commercial outlook
Standard film-coated caplet	Low	Low	High-volume, low-margin
Smaller swallowable caplet	Low to moderate	Low	Good private-label opportunity
Softgel	Moderate	Moderate	Premium pricing possible
Chewable tablet	Moderate	High taste-masking burden	Niche opportunity
Orally disintegrating tablet	Moderate	Moderate to high	Convenience-led niche
Enteric-coated product	Moderate to high	High	Differentiated but slower onset
Controlled-release product	High	High	Patentable but clinically and technically complex
Combination product	High	High	Requires broader regulatory and IP analysis

The strongest defensible position would usually come from a validated formulation platform with claims directed to a specific excipient ratio, particle engineering approach, release profile, or manufacturing process. A broad claim to “naproxen sodium 220 mg with common tablet excipients” is unlikely to provide durable protection in a crowded field.

Which companies are competing in naproxen sodium 220 mg?

The competitive market includes the Aleve brand and numerous store-brand, pharmacy-brand, warehouse-club, and e-commerce products. Competition is primarily based on:

• Retail price
• Tablet count
• Dosing duration
• Brand recognition
• Packaging
• Private-label retailer relationships
• Supply reliability
• Product claims permitted by the monograph
• Dosage-form convenience

Naproxen sodium competes directly with ibuprofen 200 mg and acetaminophen 500 mg. It also competes indirectly with aspirin products and topical analgesics.

Competitor	Typical OTC strength	Main consumer proposition
Naproxen sodium	220 mg	Longer dosing interval
Ibuprofen	200 mg	Familiarity and broad product range
Acetaminophen	325 or 500 mg	Non-NSAID analgesic positioning
Aspirin	Various	Analgesic and other legacy uses
Topical NSAIDs	Product-specific	Localized application

The strongest brand-level advantage for naproxen sodium is the association with longer-lasting relief. The strongest weakness is the same systemic NSAID safety profile that affects the category generally.

What commercial opportunities exist for manufacturers?

Private-label and contract manufacturing

The largest near-term opportunity is efficient supply of compliant caplets and tablets for retailers, pharmacy chains, warehouse clubs, and online brands. Success depends on:

• Low conversion cost
• Reliable active pharmaceutical ingredient supply
• Multi-count packaging flexibility
• High line efficiency
• Low defect rates
• Strong quality documentation
• Ability to support retailer-specific packaging

A manufacturer with validated high-speed compression, coating, bottling, blistering, and serialization capabilities can compete even without proprietary IP.

Premium convenience formats

Softgels, small caplets, coated tablets, and orally disintegrating products can support higher gross margins than commodity tablets. Premium positioning must be supported by a visible consumer benefit, such as easier swallowing, water-free dosing, or smaller unit size.

Clean-label and excipient-reduction products

Consumers increasingly scrutinize inactive ingredients. Products can be differentiated through:

• Lactose-free formulation
• Gluten-free labeling where supportable
• No artificial colors
• Reduced excipient count
• Vegan capsule shell, where applicable
• Transparent ingredient disclosure

These claims require documentary support and must not imply superior clinical safety without evidence.

E-commerce and travel packaging

Small-count blister packs, pocket packs, and unit-dose formats can target travel, workplace, sports, and emergency kits. Packaging creates a practical differentiation route because the active ingredient is commoditized.

International expansion

Naproxen sodium is marketed in multiple jurisdictions, but regulatory status, maximum OTC strength, labeling, pack size, and permitted indications vary. Geographic expansion should prioritize countries where:

• Naproxen sodium is recognized as a nonprescription ingredient.
• The 220 mg strength is accepted.
• Local manufacturing or import economics are favorable.
• Retail distribution supports branded or private-label analgesics.
• Packaging and language requirements are manageable.

A U.S. monograph strategy cannot be transferred automatically to Canada, the European Union, Latin America, or Asia-Pacific markets.

What manufacturing and intellectual-property barriers exist?

Manufacturing barriers are modest for a conventional caplet but rise sharply for differentiated formats.

Critical manufacturing risks include:

• Poor powder flow
• Segregation of low-dose excipients
• Over-lubrication
• Slow dissolution after high compression
• Coating defects
• Moisture-driven stability changes
• Inconsistent tablet weight
• API particle-size variability
• Packaging-related degradation

The active ingredient is present at a comparatively high dose, which simplifies content uniformity relative to low-dose products. The main technical control points are blend uniformity, compression behavior, dissolution, and stability.

For a differentiated formulation, IP barriers may arise from claims covering release profiles, taste-masking polymers, lipid vehicles, multiparticulates, enteric systems, or manufacturing sequences. These risks can be managed through design-around formulation work and a product-specific patent search.

When does naproxen sodium 220 mg lose exclusivity?

Naproxen sodium 220 mg has already lost practical market exclusivity. The active ingredient is mature, conventional generic products are widely available, and the OTC monograph framework supports broad competition.

Commercial exclusivity can still exist at the brand or retailer level through:

• Trademark recognition
• Exclusive distribution agreements
• Retailer contracts
• Packaging design
• Private-label relationships
• Formulation-specific patents
• Trade secrets involving manufacturing efficiency

These mechanisms can protect margin or shelf position, but they do not create molecule-level exclusivity.

How should a company prioritize development options?

A rational portfolio sequence is:

1. Launch a compliant immediate-release caplet for volume and supply-chain access.
2. Develop a smaller caplet or premium film-coated format for consumer differentiation.
3. Assess softgel or orally disintegrating formats if a premium channel is available.
4. Pursue chewable or enteric-coated products only after confirming market demand and technical feasibility.
5. Reserve controlled-release or combination products for cases with a clear clinical, regulatory, and patent strategy.

The standard caplet offers the best risk-adjusted commercial profile. Novel formats offer higher potential margin but require stronger evidence, more complex manufacturing, and greater regulatory review.

Key Takeaways

• Naproxen sodium 220 mg is a mature OTC NSAID with extensive generic and private-label competition.
• The standard product contains naproxen sodium equivalent to 200 mg naproxen.
• The most important excipient levers are disintegration, wetting, lubrication, tablet strength, coating performance, and moisture control.
• Conventional caplets have low patent risk and low development complexity.
• Softgels, chewables, orally disintegrating tablets, and enteric-coated products provide greater differentiation but carry higher technical and regulatory risk.
• The principal commercial opportunities are private label, contract manufacturing, premium convenience formats, e-commerce packs, and excipient-focused positioning.
• Biosimilar risk is irrelevant because naproxen sodium is a small-molecule drug.
• Paragraph IV litigation is generally less relevant than monograph compliance and product-specific freedom-to-operate analysis.
• Brand, packaging, formulation execution, and supply reliability are more important than molecule-level exclusivity.

FAQs

Is naproxen sodium 220 mg the same as naproxen 220 mg?

No. Naproxen sodium 220 mg is equivalent to approximately 200 mg of naproxen. The sodium salt improves handling and dissolution characteristics relative to the free acid.

Can naproxen sodium 220 mg be formulated as a liquid?

Yes, but the formulation requires careful control of solubility, taste, chemical stability, pH, preservative compatibility, and dose uniformity. A liquid product would face greater stability and packaging demands than a tablet.

Which excipient is best for rapid naproxen sodium tablet disintegration?

Croscarmellose sodium and crospovidone are common high-performance options. Final selection depends on compression force, lubricant concentration, tablet porosity, particle size, and dissolution results.

Is a naproxen sodium 220 mg product eligible for biosimilar approval?

No. Naproxen sodium is a small-molecule drug. Products are generally regulated through OTC monograph, abbreviated, or NDA-related pathways rather than the biologics biosimilar pathway.

Can a new naproxen sodium 220 mg product claim longer-lasting relief?

The product may use claims consistent with permitted labeling and substantiated comparative performance. A longer-duration claim requires appropriate evidence and cannot rely solely on the known pharmacology of naproxen sodium.

References

1. U.S. Food and Drug Administration. (n.d.). Drug facts label: Naproxen sodium 220 mg. DailyMed. https://dailymed.nlm.nih.gov/

2. Electronic Code of Federal Regulations. (n.d.). 21 C.F.R. Part 343: Internal analgesic, antipyretic, and antirheumatic drug products for over-the-counter human use. https://www.ecfr.gov/

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

4. U.S. Food and Drug Administration. (2023). Nonprescription drug products. FDA. https://www.fda.gov/drugs/over-counter-otc-nonprescription-drugs

5. United States Pharmacopeia. (2024). United States Pharmacopeia and National Formulary. U.S. Pharmacopeial Convention.